

prosci-inc.com





## HIGH PERFORMANCE ANTIBODIES ... AND MORE

**ProSci Incorporated** 12170 Flint Place Poway, CA 92064 Toll Free: +1 (888) 513 9525 Local: +1 (858) 513 2638 Fax: +1 (858) 513 2692

techsupport@prosci-inc.com

## **CDK9 Antibody**

CATALOG NUMBER: 49-409

BACKGROUND:



Immunohistochemistry staining of CDK9 in skin tissue using CDK9 Antibody.

intibody can be used in Western Blot, and immunohistochemistry starting at 2.5 ug/mL. dilutions for each application to be determined by the researcher. Intibody was raised against multiple synthetic peptides corresponding to C-Terminus of CDK9 (Human). Intibody was raised against multiple synthetic peptides corresponding to C-Terminus of CDK9 (Human). Intibody was raised against multiple synthetic peptides corresponding to C-Terminus of CDK9 (Human). Intibody was raised against multiple synthetic peptides corresponding to C-Terminus of CDK9 (Human). Intibody was raised against multiple synthetic peptides corresponding to C-Terminus of CDK9 (Human). Intibody was raised against multiple synthetic peptides corresponding to C-Terminus of CDK9 (Human). Intibody was raised against multiple synthetic peptides corresponding to C-Terminus of CDK9 (Human). Intibody was raised against multiple synthetic peptides corresponding to C-Terminus of CDK9 (Human). Intibody was raised against multiple synthetic peptides corresponding to C-Terminus of CDK9 (Human). Intibody was raised against multiple synthetic peptides corresponding to C-Terminus of CDK9 (Human). Intibody was raised against multiple synthetic peptides corresponding to C-Terminus of CDK9 (Human). Intibody was raised against multiple synthetic peptides corresponding to C-Terminus of CDK9 (Human). Intibody was raised against multiple synthetic peptides corresponding to C-Terminus of CDK9 (Human). Intibody was raised against multiple synthetic peptides corresponding to C-Terminus of CDK9 (Human). Intibody was raised against multiple synthetic peptides corresponding to C-Terminus of CDK9 (Human). Intibody was raised against multiple synthetic peptides corresponding to C-Terminus of CDK9 (Human). Intibody was raised against multiple synthetic peptides corresponding to C-Terminus of CDK9 (Human). Intibody was raised against multiple synthetic peptides corresponding to C-Terminus of CDK9 (Human). Intibody was raised against multiple synthetic peptides corresponding to C-
dilutions for each application to be determined by the researcher.  Intibody was raised against multiple synthetic peptides corresponding to C-Terminus of CDK9 (Human).  Intibody was raised against multiple synthetic peptides corresponding to C-Terminus of CDK9 (Human).  Intibody was raised against multiple synthetic peptides corresponding to C-Terminus of CDK9 (Human).  Intibody was raised against multiple synthetic peptides corresponding to C-Terminus of CDK9 (Human).  Intibody was raised against multiple synthetic peptides corresponding to C-Terminus of CDK9 (Human).  Intibody was raised against multiple synthetic peptides corresponding to C-Terminus of CDK9 (Human).  Intibody was raised against multiple synthetic peptides corresponding to C-Terminus of CDK9 (Human).  Intibody was raised against multiple synthetic peptides corresponding to C-Terminus of CDK9 (Human).  Intibody was raised against multiple synthetic peptides corresponding to C-Terminus of CDK9 (Human).  Intibody was raised against multiple synthetic peptides corresponding to C-Terminus of CDK9 (Human).
itibody was raised against multiple synthetic peptides corresponding to C-Terminus of CDK9 (Human).  ion and Defibrination  otassium phosphate, 0.15 M sodium chloride, pH 7.2, 0.01% sodium azide.  OK9 antibody at -20 °C or below prior to opening. Dilute only prior to immediate use. Aliquot contents and -20 °C or below. As with all antibodies avoid freeze/thaw cycles.
ion and Defibrination  otassium phosphate, 0.15 M sodium chloride, pH 7.2, 0.01% sodium azide.  OK9 antibody at -20 °C or below prior to opening. Dilute only prior to immediate use. Aliquot contents and -20 °C or below. As with all antibodies avoid freeze/thaw cycles.
otassium phosphate, 0.15 M sodium chloride, pH 7.2, 0.01% sodium azide.  0K9 antibody at -20 °C or below prior to opening. Dilute only prior to immediate use. Aliquot contents and -20 °C or below. As with all antibodies avoid freeze/thaw cycles.
otassium phosphate, 0.15 M sodium chloride, pH 7.2, 0.01% sodium azide.  0K9 antibody at -20 °C or below prior to opening. Dilute only prior to immediate use. Aliquot contents and -20 °C or below. As with all antibodies avoid freeze/thaw cycles.
otassium phosphate, 0.15 M sodium chloride, pH 7.2, 0.01% sodium azide.  0K9 antibody at -20 °C or below prior to opening. Dilute only prior to immediate use. Aliquot contents and -20 °C or below. As with all antibodies avoid freeze/thaw cycles.
DK9 antibody at -20 °C or below prior to opening. Dilute only prior to immediate use. Aliquot contents and -20 °C or below. As with all antibodies avoid freeze/thaw cycles.
DK9 antibody at -20 °C or below prior to opening. Dilute only prior to immediate use. Aliquot contents and -20 °C or below. As with all antibodies avoid freeze/thaw cycles.
-20 °C or below. As with all antibodies avoid freeze/thaw cycles.
gated
-2k, CDC2L4, CDC2-related kinase, Cell division protein kinase 9, Cyclin-dependent kinase 9, CDC2-rotein kinase, PITALRE, TAK, CTK1
0
ro

CDK9 (PITALRE) (also known as cyclin-dependent kinase 9, Serine/threonine-protein kinase PITALRE, C-2K and Cell division cycle 2-like protein kinase 4) is a member of the cyclin-dependent protein kinase (CDK) family. CDK family members are highly similar to the gene products of S. cerevisiae cdc28, and S. pombe cdc2, and known as important cell cycle regulators. CDK9 (PITALRE) interacts with a conserved domain in the TRAF-C region of the tumor necrosis factor signal transducer TRAF2. This kinase also was found to be a component of

the multiprotein complex TAK/P-TEFb, which is an elongation factor for RNA polymerase II-directed transcription and functions by phosphorylating the C-terminal domain of the largest subunit of RNA polymerase II. This protein forms a complex with and is regulated by its regulatory subunit cyclin T or cyclin K. HIV-1 Tat protein was found to interact with this protein and cyclin T, which suggested a possible involvement of this protein in AIDS. Tat stimulates human HIV-1 viral transcription elongation. This suggests that cyclin T1/cdk9(PITALRE) is one of the HIV-1 required host cellular cofactors generated during T cell activation. Cyclin T1/cdk9(PITALRE) is shown to interact with Tat to restore Tat activation in HeLa nuclear extracts depleted of P-TEFb. The cdk9(PITALRE) activity and cyclin T1 are essential for activation of transcription when tethered to the heterologous Rev response element RNA via the regulator of expression of virion Rev. CDK9 (PITALRE) is a ubiquitously expressed nuclear protein.

## FOR RESEARCH USE ONLY

December 13, 2016